Metformin Prostate Cancer Adjuvant Trial

Brief description of study

The purpose of the study is to determine the safety and effectiveness of Metformin can increase Prostate Specific Antigen (PSA) doubling time for patients with Prostate Cancer who have failed primary treatment with radiation, or surgical patients who are at high risk for recurrence based on surgical pathology. We want to know if the treatment will reduce signs and symptoms of the disease. Metformin is an FDA-approved drug that is prescribed to treat high blood sugar levels in patients with Type 2 Diabetes.

Clinical Study Identifier: s18-01662 Identifier: NCT02176161

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.